Pfizer expands licensing of Ingenuity Pathways Analysis software
Mountain View, CA, March 1, 2005 - Ingenuity announced today that Pfizer Inc (NYSE: PFE) has expanded its licensing of the Ingenuity Pathways Analysis software. The latest release of the Ingenuity Pathways Analysis application provides a novel approach for scientists to compare and understand biological states, a critical capability for decreasing attrition and speeding time to market in pharmaceutical research and development.
"Pfizer has embraced pathways analysis software in their research and development activities," stated Jake Leschly, President and CEO of Ingenuity. "Ingenuity is pleased to provide expanded access of Ingenuity Pathways Analysis to more Pfizer researchers."
About Ingenuity Systems
Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California. www.ingenuity.com.
> View as PDF 
|
